CD16/IL-15/CD33 (161533) Tri-Specific Killer Engagers (TriKes) for the Treatment of CD33+ Hematopoietic Malignancies

Trial Profile

CD16/IL-15/CD33 (161533) Tri-Specific Killer Engagers (TriKes) for the Treatment of CD33+ Hematopoietic Malignancies

Planning
Phase of Trial: Phase I/II

Latest Information Update: 14 Jul 2017

At a glance

  • Drugs OXS-3550 (Primary)
  • Indications Haematological malignancies
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 22 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top